Open AccessP707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC‐PHASE CHRONIC MYELOID LEUKEMIA (CP‐CML) FROM THE PACE AND OPTIC TRIALS
Author(s) -
Apperley J.,
Kantarjian H.,
Deininger M.,
Abruzzese E.,
Cortes J.,
Chuah C.,
DeAngelo D. J.,
DiPersio J.,
Hochhaus A.,
Lipton J.,
Nicolini F.,
PinillaIbarz J.,
Rea D.,
Rosti G.,
Rousselot P.,
Mauro M.,
Shah N.,
Talpaz M.,
Vorog A.,
Ren X.,
Jabbour E.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845712.36860.81
Subject(s) - ponatinib , medicine , adverse effect , clinical trial , dosing , myeloid leukemia , oncology , dasatinib , imatinib